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http://dx.doi.org/10.1016/j.kjms.201Abstract Matrix metalloproteinases (MMPs) play a critical role in the bloodebrain barrier
permeability and in invasion of the leukocytes into the central nervous system during multiple
sclerosis (MS). In this respect, in the present study, we have evaluated the possible role of
MMP-9 and MMP-2 on the expression of soluble CD154 (sCD154) and membrane-bound isoform
of the CD154 in Iranian MS patients. The expressions of the aforementioned protein-related
genes were analyzed at the levels of messenger RNA and proteins by real-time reverse tran-
scription polymerase chain reaction, enzyme-linked immunosorbent assay, and Western blot-
ting. The results showed a high expression of CD154 isoforms, MMP-9 and MMP-2, in MS
patients in contrast to controls (p < 0.001). We found an increase in sCD154 concentration
(i.e., >3-fold) in patients with a higher MMPs/tissue inhibitor of metalloproteinase 1 (TIMP-
1) ratio. Furthermore, secondary-progressive MS patients with exacerbate period showed high-
er positive correlation between increasing sCD154 concentration and overexpression of MMP-2
(p < 0.001). Our data demonstrate that following the exacerbation period, sCD154eclare no conflicts of interest.
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236 J. Sanchooli et al.concentration is increased in patients, which is mutually related to the MMPs/TIMP-1 ratio.
This relationship may represent a new link between sCD154 concentration and the MMPs/
TIMP-1 ratio with prognostic implications.
Copyright ª 2014, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Matrix metalloproteinases (MMPs) are essential enzymes in
many aspects of human development and tissue remodel-
ing. These enzymes play several important functional roles
in the pathogenesis of neuroinflammatory disorders such as
multiple sclerosis (MS) [1,2]. Recent evidence suggests that
MMPs are the major participants in disruption of the
bloodebrain barrier (BBB) in MS [3,4]. Previous studies have
reported a close association of rising levels of MMPs,
especially MMP-9 (gelatinase B), prior to an onset of exac-
erbations in humans and in the animal model of MS [5,6].
The activity of MMPs was affected by factors known as
tissue inhibitors of metalloproteinases (TIMPs) [7]. These
inhibitors are widely expressed in the extracellular milieus,
which reduce the activity of MMPs through the formation of
complexes with either activated MMPs or with their pre-
forms after their secretion [7]. Changes in the fine balance
of TIMPs and their target regulate extracellular matrix
turnover and may be critical in inflammatory processes.
CD154 (CD40 ligand, gp39, TeB cell activation molecules)
is a glycoprotein belonging to the tumor necrosis factor
ligand superfamily. Recently, two isoforms of CD154 have
been identified, which includes the membrane-bound
(mCD154) form and the soluble (sCD154) form of the pro-
tein. The mCD154 is a 33-kDa glycoprotein, which is
expressed predominantly by activated leukocytes and
platelets [8], whereas sCD154 is a 31-kDa and/or 18-kDa
glycoprotein, which can be secreted or shed from activated
cells [9]. Both isoforms of the CD154 protein are expressed at
a low level in the resting cells of myeloid and are able to
activate CD40, a 45e50-kDa type I membrane glycoprotein
from the tumor necrosis factor receptor superfamily [10,11].
The CD154 is also expressed on the surface of nonimmune
cells such as endothelial, epithelial, mesenchymal, plate-
lets, and malignant tumor cells [12e14]. Elevated levels of
sCD154 have been found in a variety of diseases in which
sCD154 has been thought to initiate or potentiate inflam-
mation [15e22]. The CD40/CD154 interactions are likely to
play a significant role in the development of autoimmune
diseases by antibodies class switching and production of
proinflammatory cytokines and costimulatory molecules
[23e25]. Given the importance of these interactions, several
anti-CD154 monoclonal antibodies, which block the CD40/
CD154 interactions, have been developed for therapeutic
applications recently [26,27].
The roles of the CD40/CD154 dyad in several autoim-
mune diseases have been studied by several independent
groups [12,15,18,21,24], whereas the role of these in-
teractions in MS remains largely unknown. In the present
matched caseecontrol study, we attempted to focus on the
relation between the expression of MMP-9, MMP-2, and
TIMP-1 and change in the concentrations of both isoforms ofCD154 in MS patients and healthy controls. In this research,
for the first time, we used a wide spectrum of clinical
techniques for evaluation of MMPs and CD154 isoforms
balances in MS courses, and to define the predictive and
prognostic value of serum sCD40L.
Materials and methods
Study population
The study, approved by the Zabol University Multiple Insti-
tutional Review Board, was conducted with all clinical sam-
ples fromMSpatientswhowere treated at theDepartment of
Neurology in the Ali Ebne Abitaleb Hospital (Zahedan, Iran)
and from healthy blood donors. The samples from volunteers
were submitted for research at the Central Medical Labora-
tory of Zahedan fromDecember 2009 to November 2011. The
MS patients (in the southeast of Iran) who had been diag-
nosed with magnetic resonance imaging and McDonald
criteria were recruited for the study [28]. We analyzed 110
different samples, including 55 patients [30 relapsing-
remitting MS (RRMS), 15 secondary-progressive MS (SPMS),
and 10 primary-progressive MS (PPMS)] and 55 age- and
gender-matched people as the healthy control group. Both
the groups comprised 20men and 35 women (mean age: 29.4
years; age range: 16e52 years). The Expanded Disability
Status Scale score for all patients at the time of inclusionwas
below the scale of 5.0, except for three individuals with SPMS
(scale 6.5) and five with RRMS (scale 5.0). All patients had an
annual relapse rate of at least 1, during 2 years prior to in-
clusion in the study. Samples from 11 patients with RRMS and
six patients with SPMS (17 samples in total) were obtained
during periods of disease exacerbation. Patients did not
receive any kind of drug treatment for at least 1week prior to
sampling.
Sampling
Serum and peripheral blood mononuclear cells (PBMCs)
were collected by standard methods described previously
[29]. These PBMCs were then mixed with 1 mL TRIzol
(Invitrogen, Carlsbad, CA, USA) and stored for RNA extrac-
tion. The aliquot samples were then stored at 80C until
further analysis. When multiple specimens were submitted
for one patient, all of them were tested more than once
and their mean value was used for analysis.
Enzyme-linked immunosorbent assay
The CD154 isoforms, MMP-9, MMP-2, and TIMP-1 were
analyzed using a specific sandwich enzyme-linked immuno-
sorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN,
MMPs and sCD154 in multiple sclerosis 237USA), according to the manufacturer’s instructions. In brief,
wells of the ELISA platewerefirst coatedwith antibodies that
captured sCD154, MMP-2, MMP-9, and TIMP-1, following
which the specimens were added to the wells [30]. Bio-
tinylated secondary antibodies and streptavidin-labeled
horseradish peroxidase (HRP) were then added to the
wells. A substrate solution [1:1 mixture of Color Reagent A
(H2O2) and Color Reagent B (tetramethylbenzidine or TMB)]
was used for visualization. Reactionswere stopped by adding
2N H2SO4. Optical density values were read at 450 nm. The
presented datawere themeans of triplicate determinations.
Western blotting
PBMCs were homogenized in a homogenizer, and the ho-
mogenate was dissolved in a specific lysis buffer as previ-
ously described [30]. Protein extracts were quantified using
the Bradford assay (Bio-Rad Laboratories, Hercules, CA,
USA). Equal amounts of total protein (20 mg) were then
boiled in sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoresis sample buffer for 10 minutes and loaded
per lane and segregated by 12.5% SDS-polyacrylamide gels
at 150 V. The resolved proteins were transferred to poly-
vinylidene difluoride membrane using tank blotting. The
membranes were washed three times in phosphate-
buffered saline (PBS) containing 0.05% (vol/vol) Tween-
20, and then blocked in 2% PBSebovine serum albumin
(wt/vol) for 2 hours. The membranes were incubated for 12
hours with primary (mouse antihuman CD154 monoclonal
antibodies) and for 2 hours in secondary (rabbit antimouse
immunoglobulin G, HRP conjugated) antibodies (R&D Sys-
tems) after washing five times in each step. Finally, the
blots were exposed to HRP substrate solution (TMB and
H2O2) for detection of target antigens. After staining, band
intensities were quantified using NIH Image 1.61 software
(National Institute of Health, Springfield, VA, USA).
Total RNA extraction and complementary DNA
synthesis
The frozen PBMCs were taken out of the refrigerator and
thawed at room temperature for 5 minutes. The total RNA
was isolated from cells using TRIzol reagent (Gibco-BRL)
according to the manufacturer’s protocol. Traces of
genomic DNA were eliminated by treating the RNA with
DNase I for 15 minutes at 37C. The resulting RNA pellet was
dissolved in diethyl pyrocarbonate-treated water and
quantitated by spectroscopy. The RNA product of 5 mL was
chosen for spectrophotometer determination. Absorbance
(A) values of RNA at 260 nm and 280 nm were determined,
and then the ratio of A260/A280 was calculated. For reverse
transcription polymerase chain reaction (RT-PCR), 2 mg of
total RNA was converted into complementary DNA (cDNA)
using first-strand cDNA synthesis kit (Fermentas) by strictly
following the manufacturer’s instructions. The productive
cDNA was stored at 20C for spare use.
Real-time RT-PCR
Message levels for CD154, TIMP-1, and MMPs, as well as for
b-actin as internal control, were determined byincorporation of SYBR green (Takara Bio Inc, Otsu, Shiga,
Japan) as detected by real-time PCR (Corbett Research,
Sydney, Australia). Specific sequences of oligonucleotide
primers used for detection are as follows: for CD154, 50-
CCAGGTGCTTCGGTGTTTGT-30 (sense), 50-ATGGCTCACTT
GGCTTGGAT-30 (antisense); for MMP-2, 50-CTATTCTGTCAG-
CACTTTGG-30 (sense), 50-CAGACTTTGGTTCTCCAACTT-30
(antisense); for MMP-9, 50-AAATGTGGGTGTACACAGGC-30
(sense), 50-TCCTTGGGGCTCTCAATTTC-30 (antisense); for
TIMP-1, 50-GACCACCTTATACCAGCGTT-30 (sense), 50-
GTCACTCTCCAGTTTGCAAG-30 (antisense); and for b-actin,
50-GACCTTCAACACCCCAGCCA-30 (sense), 50-GTCACGCAC-
GATTTCCCTCTC-30 (antisense). The Corbett Rotor-Gene 300
was used for the gene-expression analysis, making use of the
standard protocol for relative quantitative PCR. The 25-mL
reaction system included 2 Premix Ex Tag 12.5 mL, forward
and reverse primers (0.5 mL for each), 2 mL cDNA, and 9.5 mL
dH2O. The PCR protocol was as follows: predenaturation at
95C for 3 minutes, denaturation at 95C for 3 seconds,
reannealing at 56C for 30 seconds, extension at 72C for 20
seconds, with 35 cycles, followed by the final extension at
78C for 1 minute. Calculations of Ct, preparation of a stan-
dard curve, and quantification of messenger RNA (mRNA) in
each sample were performed by Rotor-Gene Operating
Software, version 1.8 (Corbett Research).
Statistical analysis
SPSS (version 20; SPSS Inc., Chicago, IL, USA) was used for
statistical analysis. Measured data were expressed as
mean  standard deviation. Differences between multiple
groups were analyzed by analysis of variance, whereas that
between the two groups were analyzed by t test. A p
value < 0.05 was taken to be significant.
Ethical considerations
The study conformed to the Helsinki Declaration and was
reviewed and approved by the local Research Committee;
written informed consentwas obtained fromall participants.
Results
Expression of CD154 isoforms (sCD154 and
mCD154)
Results showed that serum concentrations of sCD154 in MS
patients were higher than healthy controls (Table 1).
Among the different MS subtypes, SPMS patients had higher
concentration of sCD154 than other subtypes (Table 2),
whereas no significant difference was found between the
levels of sCD154 in PPMS patients and the healthy controls
(Tables 1 and 2). The serum concentration of sCD154 in the
SPMS patients was approximately twofold higher than that
in the healthy controls (Tables 1 and 2). The concentrations
of mCD154 in the PBMCs of patient groups and healthy
controls were significantly different (p < 0.001; Fig. 1),
whereas no significant difference was found between the
levels of mCD154 in the PBMCs of patient group. Interest-
ingly, patients with developmental stages of the disease
Table 1 Concentrations of MMPs, TIMP-1, and sCD154 among controls and MS patients. Serum concentrations of these mol-
ecules were measured in an automated instrument, according to the manufacturer’s instructions as described previously.
Patients (n Z 55) Controls (n Z 55) Significance (two tailed)
MMP-2 821.9  178.7 (798.1/561.1e1200.7) 695.4  192.2 (757.3/200.9e990.3) p Z 0.0005*
MMP-9 799.4  230.8 (790.3/289.3e1271.4) 576.5  149.8 (567.6/318.5e818.5) p < 0.0001*
TIMP-1 932.2  142.0 (958.3/428.5e1200.4) 1041.3  126.5 (1018.5/818.4e1367.6) p < 0.0001*
sCD154 5.1  1.3 (5.1/2.1e8.5) 3.7  0.9 (3.5/2.1e5.9) p < 0.0001*
Data are presented as mean (ng/mL)  SD (median/range).
*Significant values.
MMPZ matrix metalloproteinase; MSZmultiple sclerosis; sCD154Z soluble CD154; SDZ standard deviation; TIMP-1Z tissue inhibitor
of metalloproteinase 1.
Table 2 Concentration of MMPs, TIMP-1, and sCD154 among different subtypes of MS. Serum concentrations of these mole-
cules were measured in an automated instrument, according to the manufacturer’s instructions as described previously.
MS (n Z 55) MMP-2 MMP-9 TIMP-1 sCD154
RRMS (n Z 30) 614.1  151.6
(611.5/318.5e818.5)
714.1  208.2
(745.5/289.3e1118.5)
975.9  89.2
(990.3/814.5e1098.1)
4.6  1.2
(4.5/2.0e7.6)
SPMS (n Z 15) 945.5  148.2
(958.8/632.4e1200.7)
933.0  227.1
(957.3/517.6e1271.4)
822.8  200.2
(867.6/428.5e1200.4)
6.1  1.5
(6.4/3.2e8.5)
PPMS (n Z 10) 760.1  167.5
(723.8/567.6e1018.5)
854.9  205.6
(889.6/511.3e1068.5)
1005.3  93.4
(978.9/9011.3e1223.0)
3.6  0.4
(3.5/3.3e6.4)
Significance
(two tailed)
Subtypes (RRMS
and SPMS)
p < 0.001* p < 0.01* p < 0.01* p < 0.001*
Subtypes (RRMS
and PPMS)
p < 0.05* NS NS NS
Subtypes (SPMS
and PPMS)
p < 0.05* NS p < 0.05* p < 0.001*
Data are presented as mean (ng/mL)  SD (median/range).
*Significant values.
MMP Z matrix metalloproteinase; MS Z multiple sclerosis; NS Z not significant; PPMS Z primary-progressive MS; RRMS Z relapsing-
remitting MS; sCD154 Z soluble CD154; SD Z standard deviation; SPMS Z secondary-progressive MS; TIMP-1 Z tissue inhibitor of
metalloproteinase 1.
Figure 1. Western blot analysis of mCD40L protein in PBMCs
isolated from controls and different MS subtypes (PPMS, SPMS,
and RRMS). mCD40L Z membrane-bound CD40 ligand;
MS Z multiple sclerosis; PBMCs Z peripheral blood mono-
nuclear cells; PPMS Z primary-progressive multiple sclerosis;
RRMS Z relapsing-remitting multiple sclerosis;
SPMS Z secondary-progressive multiple sclerosis.
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mCD154 in their PBMCs (Fig. 1). The mRNA concentration of
CD154 in PBMCs in patients was significantly higher than the
control samples (p < 0.001; Fig. 2). In the patient group,
SPMS expressed significantly higher concentration of CD154-
mRNA in their PBMCs than other patients.
Expression of MMP-2, MMP-9, and TIMP-1
The mean serum concentrations of MMP-2, MMP-9, and
TIMP-1 in each group are presented in Table 2. The mean
serum concentrations of MMP-2 and MMP-9 in the patients
were significantly higher than healthy controls (p < 0.05;
Fig. 1). Among the different MS subtypes, PPMS patients
had lower concentrations of MMP-2 and MMP-9 when
compared with other subtypes (Table 2), whereas SPMS
patients had lower concentrations of TIMP-1 than other
subtypes (Table 2). Serum levels of MMP-2 and MMP-9 in the
SPMS patients were higher than other subtypes (Table 2).
The mRNA concentration of TIMP-1 in PBMCs of both groups
was relatively similar (Fig. 2). In the patient group, SPMS
patients in exacerbation period expressed significantly
higher concentration of MMP-2-mRNA in their PBMCs than
other patients (Table 3).
Figure 2. Expression of mCD40L-mRNA in PBMCs isolated
from controls, MS patients with subtypes (SPMS and RRMS) with
and without exacerbation (EC). mCD40L Z membrane-bound
CD40 ligand; mRNA Z messenger RNA; MMP Z matrix metal-
loproteinase; MS Z multiple sclerosis; PBMCs Z peripheral
blood mononuclear cells; RRMSZ relapsing-remitting multiple
sclerosis; SPMS Z secondary-progressive multiple sclerosis;
TIMP-1 Z tissue inhibitor of metalloproteinase 1.
MMPs and sCD154 in multiple sclerosis 239MMP-2/TIMP-1 and MMP-9/TIMP-1 ratios
The controls had significantly lower MMP-2/TIMP-1 and MMP-
9/TIMP-1 ratios than the study patients (Table 4). In different
MS subtypes, SPMS patients showed higher ratios of both
MMP-2/TIMP-1 and MMP-9/TIMP-1 in comparison with other
subtypes even in the exacerbation period (Table 4). The
MMP-2/TIMP-1 ratio was relatively higher in patients in the
exacerbation period than the MMP-9/TIMP-1 ratio (Table 4).
Discussion
According to this finding, it has been postulated that the
MMPs levels are in accordance with MS stages and the
severity of complications. Our findings are similar to pre-
vious studies reporting that the period of peak signs in
experimental autoimmune encephalomyelitis (EAE), an
animal model of MS, and the transcripts encoding the ma-
jority of MMPs, was elevated [31]. Specially, MMP-9 is a
proteinase establishing various disease-promoting feedbackTable 3 Concentration of MMPs, TIMP-1, and sCD154 among d
centrations of these molecules were measured with an automate
described previously.
MMP-2
RRMS with EC (n Z 11) 698.3  165.3
SPMS with EC (n Z 6) 923.2  109.8
Total patients with EC (n Z 17) 848.3  123.5
Patients without EC (n Z 38) 810.2  198.8
Significance (RRMS and SPMS; two tailed) p Z 0.0095*
Significance (total patients with EC and
patients without EC; two tailed)
NS
Data are presented as mean (ng/mL)  SD.
*Significant values.
EC Z exacerbation; MMP Z matrix metalloproteinase; MS Z multiple
sCD154Z soluble CD154; SDZ standard deviation; SPMSZ secondaryloops in autoimmune diseases. Experimental results have
shown that the MMP-2 null mice are more susceptive to EAE
because of the compensatory increase in MMP-9 in these
animals [32]. In this animal model, the increase in the level
of MMP-9 promotes the development and progression of the
disease whereas changes in the level of MMP-2 have a role
in its resolution [33]. These data suggested that the
different MMPs enzymes might have distinct roles in EAE
development, as the experiments have proven that the
double MMP-2 and MMP-9 knockout mice are resistant to
EAE development [34].
In a number of animal models, the CD154 has been
shown to be involved in the onset of inflammatory disease,
including EAE, collagen-induced arthritis, thyroiditis, uve-
itis, inflammatory bowel disease, and diabetes [35e39].
Because CD40 has been demonstrated to be expressed on
activated T cells and acted as costimulatory molecules, the
CD154/CD40 pathway is now thought to be important for
the pathogenesis and development of autoimmune dis-
eases, influencing not only the cognitive activation of an-
tigen-presenting cells (APCs) but also that of T cells [40].
Most CD154þ cells found in the brains of MS patients are
CD4þ T cells, and MS patients have a higher frequency of
CD154þ T cells than healthy controls, which decrease
following treatment with interferon-b [41]. In EAE, CD40 is
expressed in the spinal cord during acute disease and
relapse, whereas CD154 is expressed highly only during
relapse, and CD154/ mice do not develop EAE [42].
Administration of an antagonistic anti-CD154 monoclonal
antibody at the time of EAE induction prevents disease and
if treatment is given at the peak of acute disease, mice
have fewer relapses of shorter duration, correlating with
decreased Th1 cell differentiation and fewer inflammatory
cells within the central nervous system [43,44]. In other
studies, however, anti-CD154 treatment is ineffective at
alleviating EAE if given less than 7 days postimmunizations
[45]. Thus, CD40 signals appear to be more critical during
the priming stage of EAE than during established stages of
the disease. Importantly, the cleaved form of sCD154 re-
tains its ability to bind CD40 in activated target cells, acting
in a signaling manner relating to soluble cytokines [46].
Platelet CD154 can make endothelial cells activated to
produce the chemokines interleukin-8 (IL-8) and monocyteifferent subtypes of MS with exacerbation (EC). Serum con-
d instrument, according to the manufacturer’s instructions as
MMP-9 TIMP-1 sCD154
684.2  247.4 958.7  111.5 4.7  0.6
967.4  131.2 847.2  285.2 6.1  1.1
784.2  251.2 919.3  190.3 5.2  1.0
806.3  224.3 938.0  116.8 5.1  1.5
p Z 0.0206* NS p Z 0.0037 *
NS NS NS
sclerosis; NS Z not significant; RRMS Z relapsing-remitting MS;
-progressive MS; TIMP-1Z tissue inhibitor of metalloproteinase 1.
Table 4 MMP-9/TIMP-1 and MMP-2/TIMP-1 ratio in different subtypes of MS and patients with exacerbation (EC).
MMP-2/TMP-1 MMP-9/TIMP-1
RRMS (n Z 30) 0.8  0.2 0.7  0.2
SPMS (n Z 15) 1.2  0.4 1.2  0.4
PPMS (n Z 10) 0.7  0.1 0.8  0.2
Patients (n Z 55) 0.9  0.3 0.8  0.3
Patients with EC (n Z 17) 1.0  0.4 0.9  0.4
Controls (n Z 55) 0.6  0.2 0.5  0.1
Significance (two tailed) p (RRMS and controls) 0.0002* <0.0001*
p (SPMS and controls) <0.0001* <0.0001*
p (PPMS and controls) 0.0213* <0.0001*
p (patients and controls) <0.0001* <0.0001*
p (patients with EC and controls) <0.0001* <0.0001*
Data are presented as mean (ng/mL)  SD
*Significant values.
MMP Z matrix metalloproteinase; MS Z multiple sclerosis; PPMS Z primary-progressive MS; RRMS Z relapsing-remitting MS;
SD Z standard deviation; SPMS Z secondary-progressive MS; TIMP-1 Z tissue inhibitor of metalloproteinase 1.
240 J. Sanchooli et al.chemotactic protein-1 (MCP-1), which can subsequently
recruit leukocytes to areas of vascular inflammation. Once
recruited, the CD154-induced upregulation of endothelial
cell adhesion molecules E-selectin, vascular cell adhesion
molecule, and intercellular adhesion molecule 1 allows
polymorphonuclear leukocytes to bind to and potentially
extravasate across the endothelium [47]. In the context of a
mouse ischemia-reperfusion model, Ishikawa et al. [48]
showed that CD40eCD154 signaling played an integral role
in vascular permeability and compromised the function of
BBB function. Platelet-derived sCD154 was specifically
shown to induce IL-6 synthesis and cyclooxygenase-2
expression followed by downstream prostaglandin E2 pro-
duction in human lung fibroblasts [49]. Lastly, the recom-
binant CD154 as well as serum with elevated levels of
sCD154 was able to cause an increased release of MCP-1
from mononuclear cells [50].
Nevertheless, there has been no report on the effect of
MMPs/TIMPs ratios on the expression pattern of the sCD154
in MS patients. With this novel sight, we developed our
study and detected high levels of sCD154 in MS patients,
especially in the exacerbation stage. We also demonstrated
the increase in MMP-2 and the MMP-9/TIMP-1 ratios pro-
motes expression of sCD154 in SPMS more than other pa-
tients. Here, we showed that the serum concentration of
MMPs and TIMP-1 in patients with the exacerbation and
developmental stages of MS had a direct relationship with
sCD154 concentration.
In conclusion, our study showed that MMP-2, MMP-9, and
the MMPs/TIMP-1 ratios may mediate the formation of
exacerbation stage directly or as a positive feedback loop
through the sCD154 pathway. High concentration of sCD154
was observed in SPMS patients, suggesting a probable link
to disease progression and providing a basis for targeting
CD154 in the future interventions. We also recommend that
there is a special signaling pathway between CD154eCD40
interaction and MMP-2 and MMP-9 expressions. Otherwise,
it is possible that unbalanced MMPs/TIMPs expression to-
ward excessive gelatinolytic activity may contribute to
increased concentration of sCD154 and establish CD154-
dependent neuronal damage in exacerbating patients withMS. The relationship between the markers examined in our
study and the presence of disease exacerbation requires
further elucidation.Acknowledgments
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